Pacritinib: all 49 studies that test it

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingNCT07679334Phase 1
• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingNCT07447817Phase 2
• Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingNCT07394153Phase 2
• Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling InhibitorsRecruitingNCT07226713Phase 2
• Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingNCT07148947Phase 2
• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingNCT07033598Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingNCT06986174Phase 2
• A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)RecruitingNCT06782373Phase 2
• Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06675123Phase 1
• Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeRecruitingNCT06538181Phase 1
• Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingNCT06414681Early Phase 1
• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingNCT06303193Phase 1/2
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
• Pacritinib in CMMLRecruitingNCT06159491Phase 1/2
• Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingNCT06052618Phase 2
• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingNCT05531786Phase 1/2
• Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsRecruitingNCT04858256Phase 2
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate CancerTerminatedNCT04635059Phase 2Results posted
• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)TerminatedNCT02410551Phase 2Results posted
• Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal CancerTerminatedNCT02277093Phase 2Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• SB1518 for Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01436084Phase 2Results posted
• Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnNCT07387354Phase 1/2
• Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung AdenocarcinomaTerminatedNCT06516887Phase 1/2
• Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1
• A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)Active, not recruitingNCT04520269Phase 1/2
• Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Active, not recruitingNCT03645824Phase 2
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
• Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1
• PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
• To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1
• Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1
• Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1
• Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
• A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
• Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
• A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT01263899Phase 2
• A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisCompletedNCT00745550Phase 1/2
• A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT00741871Phase 1
• A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2

← Pacritinib overview